The following are excerpts from Charles Piller on Feb 11, 2025.Piller is an investigative journalist in the Science sphere, and has written these for statnews.com He is writing this piece in conjunction with his new book entitled “Doctored”, which focuses on the amyloid drugs used to treat Alzeihmers Disease. The article from which these excepts are taken is entitled “”How the amyloid mafia took over Alzeihmers research”.
“As soon as they put it in her, it was like her body was on fire,” the woman’s husband later told me. “She was screaming, and it took, like, eight people to hold her down. It was horrific.” Soon, a priest came to deliver the “Anointing of the Sick” prayer. The woman suffered seizures and was placed on a ventilator. After a few days the family approved disconnecting the device, and she died. Her doctors had never seen a case of similarly massive bleeding.
My report in Science on the death quickly became the subject of global headlines: The most promising anti-amyloid treatment was also a killer. Less than a month later, a new source came forward to tell me that her mother, another lecanemab trial participant, died after hideous brain swelling and bleeding, and violent seizures.
Lecanemab also shrinks the brain more rapidly than Alzheimer’s itself. Scientists have no clear idea what that means over the long run — and it will be impossible to find out from the key study of the drug. That’s because the drug’s maker said it would keep the data secret. No independent experts can examine the details on what happened to patients’ brains or follow what happens to them in years to come.
Targeting amyloids in the treatment of Alzeihmers disease is clearly not altogether safe. Given this is the mode or mechanism of operation where our existing FDA approved drugs come from, including drugs such as the aforementioned Lecanemab, there is a large opening for a safe and effective Alzeihmers treatment. Enter Actinogens Xanamem. If as forecast by Actinogen management Xanamem is capable of slowing and potentially halting the progression of Alzeihmers in their late phase stage 2b/3 trial being conducted in Australia and the US, in what is I might add a safe manner, then clearly the world is Dr Steven Gourlays of Actinogen’s oyster, as it were. I’m guessing he himself thinks so, having recently thrown a couple of mill from his own back pocket at the cause.
Recent M&A activity suggests there is sure to be more than a few technical traders from down under eying off Xanamem’s potential in what is a growing market space, that of dementia. As noted previously by Gourlay himself, and myself on these threads, each and every day the current trial progresses toward interim results later in 2025 is a wake up call for participants and potential entrants to ACW. A call that rings loud and clear, “If you want to hop on the Actinogen bus, you may have to pay a lot more tomorrow than you did today". From all accounts trial participant numbers are ramping up both here and in the US following the company's recent spate of media advertising. Actinogen appears to have enough money to see the trial through. Keep in mind no-one can say definitely the current Xanamem trial is a certainty when it comes to slowing and potentially halting the progression of Alzheimer patients with high levels of PTau in their system. But what one can say is that if the extensive work Actinogen is performing to deliver a successful result is anything to go by, then no stone shall be left unturned in search of a cure, or remedy for this debilitating condition.
Opinions Only
(20min delay)